Frequently Asked Questions
About the Oncotype DX Prostate Cancer Test
Q: What is the Oncotype DX Prostate Cancer Test?
The Oncotype DX prostate cancer test is a genomic test that looks at the activity of certain genes
within a sample of tumor tissue already taken from your most recent biopsy. This information can help determine how aggressive your cancer is.
Q: When should the Oncotype DX test be used?
A clinical validation study has been performed on the Oncotype DX prostate cancer test for patients with early-stage prostate cancer. The test is currently commercially available. For detailed information, please call 855-677-6782
(855 6 PROSTATE
) or visit www.oncotypeDX.com
Q: What are the benefits of the Oncotype DX test?
The Oncotype DX prostate cancer test provides a Genomic Prostate Score (GPS) that can help to predict the aggressiveness of your tumor. The information provided by the GPS about your individual disease characteristics may improve the confidence of both you and your doctor when selecting a treatment plan.
Q: Is the Oncotype DX test right for me?
If you are a man who has been recently diagnosed with low- or intermediate-risk prostate cancer, and have not yet begun treatment with surgery or radiation therapy
, the Oncotype DX test may be appropriate for you. However, the decision to use the Oncotype DX prostate cancer test is one that you and your doctor should discuss and make together.
Q: Can the Oncotype DX test be used for advanced prostate cancer?
The Oncotype DX prostate cancer test is not appropriate for men with advanced prostate cancer. To be eligible for the test, your clinical characteristics must meet the requirements of low- or intermediate-risk prostate cancer.
Q: What are the differences between Oncotype DX, Prolaris, and Decipher Biopsy*?
It is essential that all newly diagnosed prostate cancer patients, and the people who love them, understand the important distinctions between these tests so that they can get the information they need to make a well-informed, personalized treatment decision.
View Comparison Chart to learn more.
* Prolaris is a registered trademark of Myriad Genetics Inc. Decipher Biopsy is a trademark of GenomeDX Biosciences. Please refer to these manufacturers directly for more information.
Understanding the Oncotype DX Genomic Prostate Score
Q: What are the results of the Oncotype DX prostate cancer test?
The result of the Oncotype DX prostate cancer test is provided as a Genomic Prostate Score (GPS). This number, used in combination with your Gleason score and other clinical risk factors, provides a more informed view of the potential behavior of your tumor based on the individual biology of your tumor. The lower your GPS, the less likely it is that you will need immediate treatment for your prostate cancer. The higher your GPS, the more likely it is that you are a candidate for immediate treatment such as surgery or radiation therapy
Q: Does the Oncotype DX test provide the information I need to decide whether or not to receive immediate, invasive treatment for my prostate cancer?
You and your doctor will work together to make this very personal decision, but the Oncotype DX prostate cancer test is an important tool to consider using along with other clinical information when deciding whether to receive invasive treatment or choose active surveillance
. Your Oncotype DX GPS can be used to help predict the likelihood that your tumor will grow and spread. When selecting your treatment plan, you and your doctor should consider your GPS in combination with other laboratory test results, as well as your personal preferences, overall health and age.
Q: Will my Oncotype DX test result tell my doctor which treatment to use?
The result of the Oncotype DX prostate cancer test can help your doctor understand whether or not you have aggressive cancer. This information, in turn, should help your doctor recommend an appropriate level of treatment for you. If your GPS is low, he may recommend active surveillance. If your GPS is high, he may recommend surgery or radiation therapy. Your GPS should be used with other diagnostic information to help you and your doctor make a more informed decision about your treatment.
Q: Does the Oncotype DX test replace other laboratory tests?
No. The results of the Oncotype DX prostate cancer test are intended to be used together with the results of other laboratory tests that are performed to evaluate prostate cancer. These include PSA
level, Gleason score
and tumor stage
Obtaining and Ordering the Oncotype DX Test
Q: How do I get the Oncotype DX prostate cancer test?
The Oncotype DX test can only be ordered by a licensed healthcare professional. It is a test that is performed on a small tissue sample from your most recent biopsy. You do not need to undergo any additional procedures to have the Oncotype DX prostate cancer test.
Q: How long will it take to get the test results of the Oncotype DX test?
It typically takes 14 calendar days from the date the tumor sample is received by Genomic Health for the results to be available. The Genomic Prostate Score report form is sent to both your doctor and the pathologist
who submitted your tissue sample.
Q: What type of sample is needed to perform the Oncotype DX test?
The test is performed using a very small sample of the tumor tissue that was already removed from your last biopsy. In the U.S., tumor samples are commonly treated with a preservative called formalin and then embedded in paraffin wax to form a small block. The Oncotype DX process is designed for use with a small sample from this type of tissue block.
Q: How is the tumor sample submitted for the Oncotype DX analysis?
Your doctor works with a pathologist who prepares a tissue specimen from your biopsy. The pathologist uses a special kit to submit this tumor sample to the Genomic Health Laboratory for analysis.